Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study-Reference-Cited by-同舟云学术

Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study

Published:2015-04-20 Issue:4 Volume:10 Page:e0124109
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Ohta Ken,Ichinose Masakazu,Tohda Yuji,Engel Michael,Moroni-Zentgraf Petra,Kunimitsu Satoko,Sakamoto Wataru,Adachi Mitsuru

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference21 articles.

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Revised 2014. Available: http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Jun11.pdf. Accessed 12 June 2014.

2. The global burden of asthma: executive summary of the GINA Dissemination Committee report;M Masoli;Allergy,2004

3. Japanese guideline for adult asthma;K Ohta;Allergol Int,2011

4. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study;ED Bateman;Am J Respir Crit Care Med,2004

5. Understanding patients with asthma and COPD: insights from a European study;MR Partridge;Prim Care Respir J,2011

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis;Cochrane Database of Systematic Reviews;2023-08-21

2. Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses;Pulmonary Therapy;2023-08-01

3. The Role of Long-Acting Antimuscarinic Agents in the Treatment of Asthma;Journal of Aerosol Medicine and Pulmonary Drug Delivery;2023-08-01

4. Open-inhaler versus single-inhaler triple therapy (long-acting muscarinic antagonist, inhaled corticosteroid, and long-acting β₂-agonist) in asthma patients: a narrative review;Journal of Asthma;2023-04-23

5. Executive summary: Japanese guidelines for adult asthma (JGL) 2021;Allergology International;2023-04